UK markets closed

Immunicum AB (publ) (IMMU.ST)

Stockholm - Stockholm Real-time price. Currency in SEK
Add to watchlist
2.3900+0.0400 (+1.70%)
At close: 05:24PM CEST

Immunicum AB (publ)

VAestra TrAedgArdsgatan 15
Stockholm 111 53
Sweden
46 87 32 84 00
https://immunicum.se

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees32

Key executives

NameTitlePayExercisedYear born
Dr. Erik Manting Ph.D.Chief Exec. OfficerN/AN/A1971
Mr. Alex Karlsson-Parra M.D., Ph.D.Co-Founder & Chief Scientific Officer1.42MN/A1950
Ms. Lotta FermChief Financial OfficerN/AN/A1966
Dr. Leopold Bertea Ph.D.Chief Technology OfficerN/AN/A1965
Dr. Sven M. Rohmann M.D., MBA, Ph.D.Bus. Devel. AdvisorN/AN/A1962
Dr. Jeroen RoversChief Medical OfficerN/AN/A1971
Mr. Per-Olof GunnessonAdvisor ContractsN/AN/A1945
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.

Description

Immunicum AB (publ), a biopharmaceutical company, develops immunotherapies and relapse vaccines for the treatment of cancer. Its lead product is ilixadencel, which is in Phase II MERECA clinical trial for the treatment of kidney cancer; and Phase I/II clinical trial to treat liver cancer and gastrointestinal stromal tumors. The company's products also comprise DCP-001, which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia; and Phase I/II ALISON clinical trial for the treatment of ovarian cancers. It has a research collaboration with PCI Biotech Holding ASA for novel cancer vaccination treatment; and with Icahn School of Medicine at Mount Sinai. The company was incorporated in 2002 and is headquartered in Stockholm, Sweden.

Corporate governance

Immunicum AB (publ)’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.